Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Lupin updates on shipment of Mirabegron ER Tablets
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Subscribe To Our Newsletter & Stay Updated
